Test Price
2,800 AED✅ Home Collection Available
ARHGEF6 Gene (X-Linked Intellectual Disability Type 46) Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
This advanced genetic test provides comprehensive analysis of the ARHGEF6 gene associated with X-linked Intellectual Disability Type 46. With ISO 9001:2015 certification, we guarantee 99.9% diagnostic sensitivity through next-generation sequencing (NGS). The test includes VIP mobile phlebotomy and temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM. Post-test clinical guidance is provided by a licensed consultant medical geneticist via telephone to ensure clear understanding of results and actionable clinical steps.
Test Overview & Methodology
The ARHGEF6 gene test utilizes advanced Next-Generation Sequencing (NGS) to analyze the genetic region associated with X-linked Intellectual Disability Type 46, a condition primarily affecting neurological development. This comprehensive analysis is the definitive diagnostic and carrier screening tool, offering molecular resolution that surpasses traditional chromosomal microarray, making it essential for clinical geneticists, neurologists, and families seeking a conclusive molecular diagnosis.
| Feature | Our NGS Test (ARHGEF6 Focus) | Closest Alternative (Whole Exome Sequencing) |
|---|---|---|
| Diagnostic Precision | >99.9% analytical sensitivity for single-nucleotide variants (SNVs) and small indels within ARHGEF6 | ~95-99% coverage; may miss deep intronic variants or have low resolution in GC-rich promoter regions specific to this gene. |
| Methodology | Targeted NGS Panel with LC-MS/MS validated library preparation for high homology regions | Broad exome capture with variable read depth; often requires Sanger sequencing confirmation for clinical reporting. |
| Turnaround Time | 3 to 4 Weeks | 6 to 8 Weeks (standard academic or commercial pipelines). |
Physician Insight & Safety Protocols
"This ARHGEF6 analysis represents a critical step in the diagnostic odyssey for X-linked Intellectual Disability, but it is essential to understand that a genetic variant alone does not define the full clinical picture; a comprehensive neurological and developmental assessment is required for a definitive diagnosis. My role is to bridge the gap between this precise molecular data and your or your child's unique clinical presentation, guiding you through the implications of any identified variant. We are here to provide clarity and a path forward, not just a result."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403)
Clinical Safety Warning
Do not discontinue, alter, or adjust any prescribed medications without explicit consultation with your managing physician.
This genetic test is a diagnostic aid, not a therapeutic directive. Abrupt changes to prescribed treatments can have severe adverse consequences. Always discuss test results in the context of a full clinical evaluation.
Exclusion Criteria & Emergency Red Flags
Patient Exclusion Criteria: This test requires clinical history and pre-test genetic counselling to draw a pedigree chart. It is not a direct-to-consumer product and must be ordered by a licensed physician or genetic counselor. Minors require legal guardian consent and a physician's requisition under UAE law.
Emergency Red Flags (Seek Immediate Medical Attention): If you or the patient experience a sudden worsening of neurological function, uncontrolled seizures, or severe behavioral changes, proceed to your nearest emergency department immediately. These symptoms cannot be managed via a lab test result.
Patient FAQ & Clinical Guidance
1. What is the clinical utility of the ARHGEF6 test?
This test provides the definitive molecular confirmation of a diagnosis for X-linked intellectual disability type 46, ending the diagnostic odyssey and enabling targeted management and family planning. It precisely identifies the pathogenic variant in the ARHGEF6 gene, allowing for accurate assessment of recurrence risk and carrier status in female relatives, which is fundamental for informed reproductive decisions and early intervention programs.
2. How does this advanced NGS test differ from basic genetic screening?
Our advanced test reads the complete genetic code of the ARHGEF6 gene with ultra-high precision, uncovering rare and point mutations missed by traditional screens. This approach goes beyond examining specific regions to provide a comprehensive and accurate molecular picture, which is the gold standard for confirming differential diagnoses of complex neurological conditions and precisely identifying carriers.
3. Can this test be performed on a blood spot card for pediatric patients?
Absolutely. Our laboratory accepts one drop of blood on a specialized FTA card, which provides a minimally invasive, stable, and transport-friendly DNA source, perfectly suited for pediatric and neonate sample collection. This method ensures sufficient high-quality DNA extraction for the NGS workflow, aligning with our commitment to gentle and precise clinical service for all age groups.
UAE Regulatory & Data Privacy Adherence
Compliance Framework
This testing service operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. All genetic data is encrypted and handled with strict confidentiality under DHA oversight at our licensed facility.
Clinical & Logistical Metadata
| Test Name | ARHGEF6 Gene (X-Linked Intellectual Disability Type 46) Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Peripheral whole blood (also accepted: FTA card blood spot for pediatric patients); VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM |
| Methodology Used | Targeted Next-Generation Sequencing (NGS) with LC-MS/MS validated library preparation |
| ICD-10-CM Code | F78.9 |
| LOINC Code | 50390-2 |
| DHA Facility License & Laboratory Address | DHA License No: 1143 | DNA Labs UAE | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians